L-Theanine Safety in Cardiomyopathy
L-theanine appears to be safe for use in patients with cardiomyopathy based on available evidence, though caution is warranted given limited human data and one recent case report of multi-ingredient supplement-associated cardiomyopathy.
Evidence Assessment
Preclinical Safety Data
The toxicology profile of L-theanine is reassuring. A 13-week dietary toxicity study in rats found no adverse effects at doses up to 4000 mg/kg/day, establishing this as the no-observed-adverse-effect-level (NOAEL) 1. This dose far exceeds typical human consumption levels, suggesting a wide safety margin.
Potential Cardioprotective Effects
Recent preclinical research actually suggests cardioprotective properties of L-theanine in heart failure models:
In isoprenaline-induced heart failure rats, L-theanine (400 mg/kg/day) improved echocardiographic parameters (ejection fraction, fractional shortening), reduced cardiac injury markers (LDH, BNP), and modulated autophagy through the JNK/c-Jun/Beclin-1/Bcl-2 pathway 2
A comprehensive review identified L-theanine's beneficial effects on myocardial ischemia/reperfusion injury, blood pressure reduction, lipid profile improvement, and modulation of oxidative stress and inflammation 3
Proteomic and metabolomic studies demonstrate L-theanine reduces apoptosis, inflammatory pathways (IL-17, p53 signaling), and myocardial fibrosis in cardiac injury models 4
Cardiovascular Considerations
The perioperative guideline from SPAQI recommends holding L-theanine for only 24 hours before surgery due to its "dose-dependent decrease in blood pressure" 5. This short discontinuation period reflects its rapid metabolism and relatively benign safety profile compared to other supplements requiring 2-week holds.
Critical Caveat: Multi-Ingredient Supplement Risk
A 2026 case report describes severe dilated cardiomyopathy (EF 10-15%) requiring heart transplantation in a 39-year-old man who started a multi-ingredient herbal supplement containing L-theanine 6. However, this supplement contained multiple ingredients with unknown cardiovascular safety profiles, making it impossible to attribute causality to L-theanine specifically. The temporal association raises concern but does not establish direct causation.
Clinical Recommendations
For Patients Already Taking L-Theanine:
- Continue use if the patient is stable on standard cardiomyopathy therapy (ACE inhibitors/ARBs, beta-blockers, diuretics as indicated) 7, 8
- Monitor blood pressure, as L-theanine may have mild hypotensive effects 5
- Ensure the patient is taking pure L-theanine, not multi-ingredient formulations with unknown cardiac effects 6
For Patients Considering L-Theanine:
May initiate with close monitoring, particularly in patients with:
- Baseline hypotension or on multiple vasodilators
- Advanced heart failure (NYHA Class III-IV) requiring careful hemodynamic balance 8
Start with lower doses and titrate based on tolerance
Avoid multi-ingredient supplements entirely given the case report of severe cardiomyopathy 6
Contraindications Based on Cardiomyopathy Guidelines:
While L-theanine is not specifically mentioned in cardiomyopathy guidelines 7, 8, 9, 10, apply general principles:
- Avoid if patient has symptomatic hypotension or is already on maximum vasodilator therapy
- Use caution in hypertrophic cardiomyopathy with outflow obstruction, where vasodilation could theoretically worsen gradients (though this is speculative) 9
Monitoring Parameters
If L-theanine is used:
- Blood pressure at each visit
- Symptoms of worsening heart failure (dyspnea, edema, fatigue)
- Standard cardiomyopathy monitoring per guidelines (BNP, echocardiography, electrolytes) 7, 8
Key Pitfalls to Avoid
Do not assume all "natural" supplements are safe - the case report demonstrates potential for severe cardiac toxicity with multi-ingredient formulations 6
Do not overlook supplement history - specifically ask about L-theanine and other supplements in unexplained heart failure or cardiomyopathy deterioration 10, 6
Do not combine with other vasodilators without monitoring - additive hypotensive effects possible with nitrates, calcium channel blockers, or phosphodiesterase inhibitors 7, 9
Do not use as substitute for guideline-directed medical therapy - L-theanine should never replace ACE inhibitors, beta-blockers, or other evidence-based cardiomyopathy treatments 7, 8